Not checkedNot checked for notices yet.
B cell counterpart of Treg cells: As a new target for autoimmune disease therapy
Myong-Guk Ri, Chol-Ho Kang
Indian Journal of Allergy Asthma and Immunology · 2019
doi:10.4103/ijaai.ijaai_27_18 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
B cells have been considered a positive immune regulator by producing antibodies and presenting antigens to T cells. Recently, it has been shown that B cells comprise rare but potent subset capable of inhibiting immune responses via diverse regulatory mechanisms. This subset of B cells, known as regulatory B cells (Bregs), negatively regulates immune responses and contributes to immune tolerance. Among several regulatory B cell subsets, interleukin 10 (IL-10)-producing regulatory B cells are intensively investigated. Studies in experimental animal models, as well as in patients with autoimmune diseases, have identified Breg subsets exhibiting a powerful therapeutic tool for severe immune disorders. Now, human regulatory B cells are becoming an active area of research. Clear criteria to identify these cell subsets and the key molecular mechanisms underlying their physiological features are required for understanding the complete picture of regulatory B cells. This review highlights the current knowledge on regulatory B cells, mainly IL-10-producing regulatory B cells.
Abstract licence: CC BY-NC-SA
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.